# BioNTech SE American Depositary Share (BNTX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $103.76, market value $26.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). BioNTech SE American Depositary Share reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 8.5×**. Each dollar of revenue is priced at 8.5×.
- **Price / book: 1.3×**. The shares trade at 1.3× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: 2.0%** (5-yr avg 11.7%). Free cash flow equals 2.0% of the market value, below its five-year average of 11.7%, so the shares are pricier on cash than usual.

## Profitability
- **Gross margin: 75.5%**. BioNTech SE American Depositary Share keeps 75.5% of revenue after the direct cost of what it sells, the kind of margin that comes with software, brands or pricing power.
- **Operating margin: -46.7%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -39.6%**. The company reported a net loss over the last twelve months.
- **Return on equity: -5.9%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -10.5%**. Return on all capital, debt included, is -10.5%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -7.7%**. Each dollar of assets produces -7.7% of profit.

## Growth
- **Revenue growth (1 yr): 4.3%** (3-yr -45.1%/yr, 5-yr 42.9%/yr). Revenue grew 4.3% over the last year, against 42.9% a year compounded over five years: growth is slowing.
- **EPS growth (1 yr): -69.7%**. Earnings per share fell 69.7%, slower than revenue, so margins compressed.
- **Free-cash-flow growth (3 yr): -72.3%/yr**. Free cash flow has compounded at -72.3% a year over three years.

## Financial health
- **Debt to equity: 0.01**. Debt is 0.01 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 9.8×**. It would take 9.8 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Current ratio: 7.54** (quick 7.54). Current assets cover the next year's liabilities 7.54 times.
- **Altman Z-score: 7.57**. A Z-score of 7.57 places the company in the safe zone for bankruptcy risk.
- **Piotroski F-score: 4/9**. 4 of 9 checks pass: mixed.

## Dividends
- **Dividend: none**. BioNTech SE American Depositary Share does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (20 analysts). 20 analysts cover BioNTech SE American Depositary Share; the consensus is buy, with an average price target of $120.35 (+16% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 0.3%** (YTD 9.0%, 3-mo 17.8%). The shares are up 0.3% over twelve months including dividends.
- **From 52-week high: -16.3%** (30.5% above the low). Trading 16% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 54**. An RSI of 54 is neutral.
- **Beta (1 yr): 0.90** (volatility 48%). Beta of 0.90 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=BNTX · Page: https://foliofundamentals.com/stocks/bntx

Not investment advice.